Levi & Korsinsky is investigating potential claims on behalf of purchasers of Vanda Pharmaceuticals, Inc. (“Vanda” or the “Company”) (NasdaqGM: VNDA) stock. The investigation stems from concerns regarding the Company’s Phase III trials for the drug Tasimelteon.
For more information, click here:
On May 31, 2013, Vanda submitted a New Drug Application (“NDA”) for Tasimelteon to the U.S. Food and Drug Administration. Then on June 19, 2013, an article was published on thestreet.com, questioning the efficacy of Vanda’s study, noting that the study not only changed multiple times, but that it replaced the primary endpoint just a month before study results were announced; this replacement primary endpoint was not endorsed by the FDA and had never been used in clinical trials for this type of medication. On the news, shares of Vanda closed at $8.51 per share on June 19, 2013, a drop of more than 20% from the previous day.
If you own Vanda stock and wish to obtain additional information about the investigation and your legal rights, please contact Joseph E. Levi, Esq. either via email at
or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit
Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.